RU2003133973A - Анти-человечно-яичниково-карциномное и анти-человечно-анти-cd-3, биспецифическое антитело - Google Patents
Анти-человечно-яичниково-карциномное и анти-человечно-анти-cd-3, биспецифическое антитело Download PDFInfo
- Publication number
- RU2003133973A RU2003133973A RU2003133973/13A RU2003133973A RU2003133973A RU 2003133973 A RU2003133973 A RU 2003133973A RU 2003133973/13 A RU2003133973/13 A RU 2003133973/13A RU 2003133973 A RU2003133973 A RU 2003133973A RU 2003133973 A RU2003133973 A RU 2003133973A
- Authority
- RU
- Russia
- Prior art keywords
- ser
- thr
- gly
- leu
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Claims (22)
1. Анти-яичниково-карциномное биспецифическое антитело, созданное соединением анти-яичниково-карциномного антитела или его Fab фрагмента, однодоменного или антицепочечного антитела с анти-человечно-CD3-антителом или его Fab фрагментом, однодоменным или одноцепочечным антителом.
2. Антитело по п.1, отличающееся тем, что анти-человечно-CD3-одноцепочечное антитело является реформатским.
3. Антитело по п.2, отличающееся тем, что имеет следующую аминокислотную последовательность тяжелого изменчивого домена:
1 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu
11 Val Lys Lys Pro Gly Glu Thr Val Arg Ile
21 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
31 Thr Ala Gly Met Gln Trp Val Gln Lys Met
41 Pro Gly Lys Gly Leu Lys Trp Leu Gly Trp
51 Ile Asn Thr Asn Ser Glu Val Pro Lys Tyr
61 Ala Glu Asp Phe Arg Gly Arg Phe Ala Phe
71 Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
81 Leu Gln Ile Ser Asn Leu Lys Asn Glu Asp
91 Thr Ala Thr Phe Phe Cys Ala Arg Ser Phe
101 Thr Trp Gly Thr Met Asp Tyr Trp Gly Gln
111 Gly Thr Thr Val Thr Val Ser Ser
4. Антитело по п.2, отличающееся тем, что анти-яичниково-карциномное одноцепочечное антитело имеет следующую последовательность легкого изменчивого домена:
1 Asp Val Val Met Thr Gln Thr Pro Leu Ser
11 Leu Pro Val Ser Leu Gly Asp Gln Ala Ser
21 Ile Ser Cys Arg Ser Ser Gln Thr Leu Val
31 His Ser Ile Gly Asn Thr Tyr Leu His Trp
41 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys
51 Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe
61 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
71 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
81 Ser Arg Val Glu Ala Glu Asp Leu Gly Val
91 Tyr Phe Cys Ser Gln Ser Thr His Val Pro
101 Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu
111 Leu Lys
5. Антитело по п.2, отличающееся тем, что анти-человечно-CD3 реформатское одноцепочечное антитело имеет следующую аминокислотную последовательность тяжелого изменчивого домена:
1 Gln Val Gln Leu Val Gln Ser Gly Ala Glu
11 Val Arg Lys Pro Gly Ala Ser Val Arg Val
21 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
31 Arg Tyr Thr Met His Trp Val Arg Gln Ala
41 Pro Gly His Gly Leu Glu Trp Ile Gly Tyr
51 Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr
61 Asn Gln Lys Phe Lys Asp Arg Val Thr Met
71 Thr Thr Asp Lys Ser Phe Ser Thr Ala Ile
81 Met Asp Leu Arg Ser Leu Arg Ser Asp Asp
91 Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr
101 Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly
111 Gln Gly Thr Thr Val Thr Val Ser Ser
6. Антитело по п.2, отличающееся тем, что анти-человечно-CD3 реформатское одноцепочечное антитело имеет следующую аминокислотную последовательность легкого изменчивого домена:
1 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr
11 Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr
21 Leu Ser Cys Ser Ala Ser Ser Ser Val Ser
31 Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly
41 Gln Ala Pro Arg Arg Trp Ile Tyr Asp Thr
51 Ser Lys Leu Ala Ser Gly Ile Pro Ala Arg
61 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
71 Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
81 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp
91 Ser Ser Asn Pro Phe Thr Phe Gly Gly Gly
101 Thr Lys Val Glu Ile Lys Arg
7. Антитело по п.2, отличающееся тем, что интерклинкер, соединяющий два одноцепочечных антитела имеет следующую аминокислотную последовательность:
1 Asn Ser Thr Tyr Arg Val Val Ser Val Leu
11 Thr Val Leu His Gln Asp Trp Leu Asn Gly
21 Lys Glu Tyr Lys Cys Lys
8. Антитело по п.2, отличающееся тем, что интерклинкер, соединяющий два одноцепочечных антитела имеет следующую аминокислотную последовательность:
1 Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr
11 Lys Lys Val Pro Gln Val Ser Thr Pro Thr
21 Leu Val Glu Val Ser
9. Антитело по п.2, отличающееся тем, что интерклинкер, соединяющий два одноцепочечных антитела имеет следующую аминокислотную последовательность:
1 Ala Ser Ala Asp Asp Ala Lys Lys Asp Ala
11 Ala Lys Lys Asp Asp Ala Lys Lys Asp Asp
21 Ala Lys Lys Asp Leu
10. Нуклеотидная последовательность, кодирующая биспецифическое антитело от антител по пп.1-9.
11. Экспрессирующий вектор, содержащий нуклеотидную последовательность от антитела по п.10
12. Вектор по п.11, отличающийся тем, что он является pALM.
13. Вектор по п.11, отличающийся тем, что является рЕТΔЕ.
14. Вектор по п.11, отличающийся тем, что является pTMF.
15. Хозяин-клетка, отличающаяся тем, что содержит вектор по п.11.
16. Хозяин-клетка по п.15, отличающаяся тем, что она является E.coli.
17. Лекарственный комплекс для лечения и превенции опухолей, содержащий биспецифическое антитело и лекарственный вектор по любому пп.1-9.
18. Лекарственный комплекс по п.17, отличающийся тем, что применяется также, если опухоль является яичниково-карциномой.
19. Применение антитела по пп.1-9 при изготовлении лекарства для лечения и превенции опухоли.
20. Применение по п.19, отличающееся тем, что опухоль является яичниково-карциномой.
21. Применение биспецифического антитела по пп.1-9 для лечения и превенции опухоли.
22. Применение по п.21, отличающееся тем, что опухоль является яичниково-карциномой.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011182474A CN1195779C (zh) | 2001-05-24 | 2001-05-24 | 抗人卵巢癌抗人cd3双特异性抗体 |
CN01118247.4 | 2001-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2003133973A true RU2003133973A (ru) | 2005-05-10 |
Family
ID=4663054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2003133973/13A RU2003133973A (ru) | 2001-05-24 | 2002-05-23 | Анти-человечно-яичниково-карциномное и анти-человечно-анти-cd-3, биспецифическое антитело |
Country Status (8)
Country | Link |
---|---|
US (2) | US7262276B2 (ru) |
EP (1) | EP1394253B1 (ru) |
CN (1) | CN1195779C (ru) |
AT (1) | ATE454903T1 (ru) |
DE (1) | DE60235079D1 (ru) |
ES (1) | ES2337237T3 (ru) |
RU (1) | RU2003133973A (ru) |
WO (1) | WO2003004648A1 (ru) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
CN1326881C (zh) * | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体,其制备方法及用途 |
DK1673398T3 (da) | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecifikke, deimmuniserede CD3-bindere |
WO2006009901A2 (en) * | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
MX2007000387A (es) * | 2004-07-16 | 2007-03-28 | Micromet Ag | Polipeptidos de expresion mejorada. |
DE102007030904A1 (de) * | 2007-07-03 | 2009-02-05 | Pharis Biotec Gmbh | Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung |
US9050375B2 (en) * | 2009-07-06 | 2015-06-09 | Hoffmann-La Roche, Inc. | Bi-specific digoxigenin binding antibodies |
CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
WO2011139985A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2828347A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
KR101963230B1 (ko) | 2011-12-26 | 2019-03-29 | 삼성전자주식회사 | 복수개의 단일 항체를 포함하는 단백질 복합체 |
US9765156B2 (en) | 2012-07-13 | 2017-09-19 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
WO2014079000A1 (en) * | 2012-11-21 | 2014-05-30 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
EP3105252B1 (en) | 2014-02-12 | 2019-07-24 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
EP4039710A3 (en) | 2015-01-23 | 2022-10-19 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
EP3294319B1 (en) * | 2015-05-13 | 2024-04-24 | Ablynx NV | T cell recruiting polypeptides based on cd3 reactivity |
ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102365977B1 (ko) * | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
WO2017201488A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
CN106117358A (zh) * | 2016-06-16 | 2016-11-16 | 中山大学 | 抗cd3单域抗体 |
CN106146661A (zh) * | 2016-06-17 | 2016-11-23 | 中山大学 | 抗cd3单域抗体 |
CN106084047A (zh) * | 2016-06-17 | 2016-11-09 | 中山大学 | 抗cd3单域抗体 |
CN106084049A (zh) * | 2016-06-17 | 2016-11-09 | 中山大学 | 抗cd3单域抗体 |
KR20190053835A (ko) | 2016-06-21 | 2019-05-20 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
CN106146662A (zh) * | 2016-07-18 | 2016-11-23 | 中山大学 | 抗cd3单域抗体 |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
JP7254699B2 (ja) | 2016-12-21 | 2023-04-10 | テネオバイオ, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
EP4230649A3 (en) | 2017-04-25 | 2023-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
CN117567624A (zh) | 2017-06-20 | 2024-02-20 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
KR20200018498A (ko) | 2017-06-20 | 2020-02-19 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS |
EP3676294A4 (en) * | 2017-08-28 | 2021-12-22 | Systimmune, Inc. | ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF |
CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
BR112020007196A2 (pt) | 2017-10-13 | 2020-12-01 | Harpoon Therapeutics, Inc. | proteínas triespecíficas e métodos de uso |
MX2020006715A (es) | 2017-12-27 | 2020-08-20 | Teneobio Inc | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. |
CA3082280A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1 |
EP3788071A1 (en) | 2018-05-02 | 2021-03-10 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
AR119746A1 (es) | 2019-06-14 | 2022-01-05 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
CN115894703A (zh) | 2020-04-29 | 2023-04-04 | 特尼奥生物股份有限公司 | 具有经修饰重链恒定区的多特异性重链抗体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2063035A1 (en) | 1991-03-27 | 1992-09-28 | Klaus Karjalainen | Chimaeric antibodies containing the ligand domain of cd4 |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6025165A (en) * | 1991-11-25 | 2000-02-15 | Enzon, Inc. | Methods for producing multivalent antigen-binding proteins |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
US6329507B1 (en) * | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
US6146628A (en) * | 1995-07-11 | 2000-11-14 | Regents Of The University Of Minnesota And Rutgers | Biotherapeutic agents comprising recombinant PAP and PAP mutants |
CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
-
2001
- 2001-05-24 CN CNB011182474A patent/CN1195779C/zh not_active Expired - Fee Related
-
2002
- 2002-05-23 WO PCT/CN2002/000347 patent/WO2003004648A1/zh not_active Application Discontinuation
- 2002-05-23 US US10/478,345 patent/US7262276B2/en not_active Expired - Fee Related
- 2002-05-23 AT AT02734983T patent/ATE454903T1/de not_active IP Right Cessation
- 2002-05-23 RU RU2003133973/13A patent/RU2003133973A/ru not_active Application Discontinuation
- 2002-05-23 ES ES02734983T patent/ES2337237T3/es not_active Expired - Lifetime
- 2002-05-23 EP EP02734983A patent/EP1394253B1/en not_active Expired - Lifetime
- 2002-05-23 DE DE60235079T patent/DE60235079D1/de not_active Expired - Lifetime
-
2007
- 2007-08-22 US US11/895,207 patent/US20080138339A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050255115A1 (en) | 2005-11-17 |
ATE454903T1 (de) | 2010-01-15 |
EP1394253A1 (en) | 2004-03-03 |
EP1394253B1 (en) | 2010-01-13 |
CN1388136A (zh) | 2003-01-01 |
WO2003004648A1 (fr) | 2003-01-16 |
US7262276B2 (en) | 2007-08-28 |
DE60235079D1 (de) | 2010-03-04 |
ES2337237T3 (es) | 2010-04-22 |
EP1394253A4 (en) | 2006-03-15 |
CN1195779C (zh) | 2005-04-06 |
US20080138339A1 (en) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2003133973A (ru) | Анти-человечно-яичниково-карциномное и анти-человечно-анти-cd-3, биспецифическое антитело | |
Hudson et al. | High avidity scFv multimers; diabodies and triabodies | |
Lu et al. | Di-diabody: a novel tetravalent bispecific antibody molecule by design | |
Lu et al. | The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody | |
Le Gall et al. | Di-, tri-and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding | |
Todorovska et al. | Design and application of diabodies, triabodies and tetrabodies for cancer targeting | |
CN109641046A (zh) | 单链可变片段cd3结合蛋白质 | |
JP2020501531A5 (ru) | ||
RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
WO2012020622A1 (ja) | ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用 | |
JP2014530017A5 (ru) | ||
JP2003523771A5 (ru) | ||
RU2003130072A (ru) | Одноцепочечное цикличное триспецифическое антитело | |
RS51829B (sr) | Ljudska antitela specifična za interleukin 15 (il-15) | |
RU2005116225A (ru) | Антитела, специфичные к фактору некроза опухолей, и их применение | |
Lu et al. | Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments | |
HRP20150934T1 (hr) | Djelovanje na abcb5 u terapiji raka | |
JP2018509887A5 (ru) | ||
HRP20030805B1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
JP2020529839A5 (ru) | ||
JP2020522473A5 (ru) | ||
Benhar et al. | Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs Bl and B5 as single-chain immunotoxins | |
HRP20150457T1 (hr) | Lijekovi protiv pemfigusa koji sadrže anti-fas lagand antitijela | |
JP2019524640A5 (ru) | ||
AU2021398150A1 (en) | ANTI-SIRPα ANTIBODY AND APPLICATION THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20060830 |